What Happened — KOSDAQ Crash on June 24, 2026
On the morning of June 24, 2026 (all figures as of that date), shares of KOSDAQ-listed biotech company Shaperon (378800) plummeted -29.15%, approaching the daily lower limit. Trading volume reached approximately 4.09 million shares — the highest on the KOSDAQ that day — reflecting the intensity of selling pressure and investor attention.
PrimeEconomy ran an after-hours alert headlined “[After-Hours Y] Shaperon ‘Lower Limit,’” confirming the depth of the selloff. CBC News followed with a breaking headline: “[Breaking] Shaperon’s atopic dermatitis treatment HY209 Gel misses primary endpoint in Phase 2 trial.”
Why the Crash — Phase 2 Trial Misses Primary Endpoint
The direct cause is a clinical trial failure. Shaperon disclosed that its atopic dermatitis candidate HY209 Gel (brand name: NuGel) failed to meet the primary endpoint in a U.S. Phase 2b trial.
The Korea Economic Daily reported “Shaperon atopic dermatitis treatment misses primary endpoint in Phase 2 trial” (Korea Economic Daily, June 24, 2026). Newsis headlined “Shaperon’s ‘atopic new drug’ misses primary endpoint in Phase 2.” Multiple specialized pharma outlets — including Yaksa Gongnon, HitNews, and Digital Today — used the phrase “failed to secure efficacy” in their coverage.
According to DataInvestment’s report, Shaperon stated it plans to “adjust its pipeline based on the final report results expected in September.” DailyPharm followed up with “NuGel U.S. Phase 3 strategy takes shape… additional trial under review,” suggesting the company has not abandoned the program — but the time and capital requirements for further trials are likely to be significant.
Background — The NuGel Pipeline and Company Context
Shaperon is an inflammation and immunology-focused biotech. NuGel (HY209 Gel) was one of its flagship pipeline assets. Atopic dermatitis is a large indication affecting hundreds of millions globally, and a successful U.S. approval would have held substantial commercial value.
Even before this trial failure, Shaperon had been navigating a complex corporate situation. ParmEDaily and Dealsite covered the company’s decision to acquire a stake in NizTech, a beauty device company, framing it as a diversification move amid “legal accumulated deficit” concerns (first half of 2026). The Phase 2 miss adds uncertainty to the core pipeline and could weigh on future fundraising capacity.
Key Points to Watch — What Comes After a Trial Failure
- What “primary endpoint miss” means: Failing the primary endpoint means the trial did not achieve its main goal. Secondary analyses may still show some positive signals, but the critical gate for regulatory approval has not been cleared.
- Time and capital burden of further trials: DailyPharm reported that Shaperon is considering Phase 3 options, but additional pivotal trials typically require several years and hundreds of millions of Korean won or more. The company’s financial runway is a key variable.
- Ongoing uncertainty before the September report: The final trial report is expected in September 2026. Until then, share price volatility may persist as the market waits for fuller data.
Disclaimer
This article is provided for informational purposes only as a market commentary and does not constitute a recommendation to buy or sell any specific security, nor investment advice of any kind. All investment decisions and their outcomes are the sole responsibility of the individual investor. Figures are based on data available as of the morning of June 24, 2026, and are subject to change with market conditions.
Leave a Reply